Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
All news
Pharmaceutical
India's G20 presidency has turned the spotlight on the country's prowess in the pharmaceutical space. 13 September 2023
Pharmaceutical
US genomics-based drug discovery company Exelixis has entered into an exclusive license agreement with Sino-American firm Insilico Medicine for global rights to develop and commercialize the latter’s ISM3091. 13 September 2023
Pharmaceutical
Oral phenylephrine has for years generated major revenues as an over-the-counter decongestant, but a meeting of the US Food and Drug Administration’s scientific experts has thrown a wrench in the works. 13 September 2023
Pharmaceutical
The European Medicines Agency (EMA) has validated Japanese pharma major Astellas Pharma’s Type II variation for Xtandi (enzalutamide) for the treatment of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). 13 September 2023
Pharmaceutical
With the European Commission Decision Reliance Procedure (ECDRP) due to come to an end on December 31, 2023 - subject to consultation - the UK’s Medicines and Healthcare Regulatory Agency (MHRA) will launch a new International Recognition Procedure (IRP) from January 1, 2024. 12 September 2023
Pharmaceutical
A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance (AMR). 12 September 2023
Pharmaceutical
US clinical-stage liver disease drug developer Madrigal Pharmaceuticals today announced that Bill Sibold has succeeded Dr Paul Friedman as the firm’s chief executive and joined Madrigal’s board of directors. 11 September 2023
Pharmaceutical
Florida, USA-based biotech Veru has expressed its confidence in breast cancer candidate enobosarm, citing data from a discontinued Phase III trial. 11 September 2023
Pharmaceutical
Around 180,000 people in England and Wales with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by the National Institute for Health and Care Excellence (NICE. 11 September 2023
Pharmaceutical
The Belgian pharmaceutical industry has responded to reports of medicine shortages, with local media attributing the blame in some cases to the actions of pharmaceutical companies. 11 September 2023
Pharmaceutical
Shares of US drug developer Crinetics Pharmaceuticals shot up more than 66%% to $26.60 pre-market, after its experimental treatment for a rare hormonal disorder not only succeeded, but performed better than Wall Street expectations. 11 September 2023
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has accepted for review a new drug application (NDA) for momelotinib, filed by UK pharma major GSK. 11 September 2023
Pharmaceutical
Multi-stakeholder group consisting of 32 European patient organizations, medical associations, research organizations, data collaborations and industry associations consider EHDA opt-out. 11 September 2023
Pharmaceutical
Boston, USA-based Glyscend Therapeutics, which is developing a revolutionary approach to treating type 2 diabetes, has appointment of Sapan Shah as chief executive (CEO). 8 September 2023
Pharmaceutical
US biopharma CymaBay Therapeutics traded up as much as 21% to $16.73 yesterday, as the company released encouraging trial results for its primary biliary cholangitis (PBC) candidate after earlier disappointments. 8 September 2023
Pharmaceutical
UK cancer and infectious disease drug developer Scancell Holdings has appointed Dr Mandeep Sehmi as head of business development, effective immediately. 8 September 2023
Pharmaceutical
After years of uncertainty stemming from the UK’s departure from the European Union (EU), Prime Minister Rishi Sunak has confirmed that, from Thursday onwards, British scientists can apply once again for grants from the £85 billion ($106 billion) Horizon program. 7 September 2023
Pharmaceutical
Swiss drugmaker Novartis has launched legal action against the US government, after administrators revealed the first drugs to be subject to pricing regulations mandated by the Inflation Reduction Act (IRA). 7 September 2023
Pharmaceutical
Japanese pharma major Astellas Pharma revealed that it has requested that the Court dismiss the company’s lawsuit challenging the constitutionality of certain provisions of the US government’s Inflation Reduction Act (IRA). 7 September 2023
Pharmaceutical
Cardiometabolic med Jardiance (empagliflozin), a blockbuster product developed by Boehringer Ingelheim and Eli Lilly, has picked up a new approval in the UK. 7 September 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze